Abstract: Reduced degeneration of an axon predetermined to be subject to degenerative neuropathy in a term patient is effected by contacting the axon in situ with an effective amount of a ubiquitin-proteasome system (UPS) inhibitor sufficient to reduce degeneration of the axon; and detecting a resultant reduction in the degeneration of the axon in situ.

Abstract: The present invention relates generally to immunization methods using recombinant viral vectors. In particular, the invention relates to methods and compositions for immunizing a subject with a nucleic acid molecule encoding an antigen of interest, wherein the nucleic acid molecule is delivered to the subject via a recombinant AAV virion.

Abstract: The human DNA polymerase &agr; catalytic polypeptide has been functionally over-expressed by a recombinant baculovirus in insect cells at >1000 fold higher levels than that found in cultured normal human cells.

Abstract: A method for forming an adaptive phased array transmission beam pattern at a base station without any knowledge of array geometry or mobile feedback is described. The approach is immune to the problems which plague methods which attempt to identify received angles of arrival from the mobile and map this information to an optimum transmit beam pattern. In addition, this approach does not suffer the capacity penalty and mobile handset complexity increase associated with mobile feedback. Estimates of the receive vector propagation channels are used to estimate transmit vector channel covariance matrices which form objectives and constraints in quadratic optimization problems leading to optimum beam former solutions for the single user case, and multiple user case. The new invention in capable of substantial frequency re-use capacity improvement in a multiple user cellular network.

Abstract: This invention provides a method for treating or preventing arrhythmias in a human subject comprising the administration of an effective amount of a calcium/calmodulin-dependent protein kinase inhibitor. Also provided are pharmaceutical compositions comprising a calcium/calmodulin-dependent protein kinase inhibitor and a pharmaceutically acceptable carrier and methods for identifying agents useful for the treatment of arrhythmias.

Abstract: This invention is directed to novel catalysts the structure and activity of which can be controlled to produce a wide range of alpha olefin polymers and co-polymers, and preferably for the production of stereoblock poly alpha olefins comprising a wide range of preselected amorphous and crystalline segments for precise control of the physical properties thereof, principally elastomeric thermoplastic properties. More specifically, this invention is directed to novel catalysts and catalysts systems for producing stereoblock polypropylene comprising alternating isotactic and atactic diastereosequences, which result in a wide range of elastomeric properties. The amount and numbers of crystalline sections, the isotactic pentad content, the number and length of intermediate atactic chains and overall molecular weight are all controllable by the steric structure of the catalysts and the process conditions.

Abstract: This invention relates generally to low ethylene insertions into I-olefin polymers and processes for production of such polymers using unbridged fluxional metallocenes, primarily substituted aryl indenyl metallocenes, and more particularly to use of unbridged, fluxional, cyclopentadienyl or indenyl metallocene catalyst systems in methods of production of high melting point I-olefin homo- and co-polymers, particularly elastomeric crystalline and amorphous block homo- and co-polymers of I-olefins. The activity of fluxional unbridged metallocene polymerization catalysts containing at least one 2-arylindene ligand is increased 10× or more by the addition of small (typically 0.1-10 wt. %) amounts of ethylene to the polymerization system, which increase is termed the Polymerization Rate-Enhancement effect (PRE), which is measured in terms of an Ethylene Enhancement Factor (EEF) as a dimensionless ratio in the range of from about 1.1 to about 10 or above.

Abstract: A VLSI layout editor and method for using same that increases display and re-display speed and accuracy uses properties inherent to VLSI layouts that allows them to be displayed efficiently and accurately independent of the canonical expression of the VLSI design. The VLSI layout editor and methods for using same use precomputed images that each represent a portion of the VLSI layout, a hierarchy cache that includes multiple LOD versions of selected sub-designs in the pre-computed images, and selected direct determination of the viewable representation from the canonical expression for at least one LOD. Apparatus and methods according to the present invention can render a particular type of data whose canonical form is smaller than its corresponding displayed image thereof when the displayed image has geometric properties that allow heuristics and rasterization for dynamic and accurate expansion using selected combined techniques.

Abstract: Osteopontin (OPN) levels measured in bodily fluids of cancer patients are used as a noninvasive marker for tumor hypoxia as described herein. Methods of using OPN levels for the diagnosis, prognosis and treatment of cancers characterized by the presence of hypoxic cells, and a kit for detecting the presence of a hypoxic tumor are provided.

Abstract: This invention provides a method for treating or preventing arrhythmias in a human subject comprising the administration of an effective amount of a calcium/calmodulin-dependent protein kinase inhibitor. Also provided are pharmaceutical compositions comprising a calcium/calmodulin-dependent protein kinase inhibitor and a pharmaceutically acceptable carrier and methods for identifying agents useful for the treatment of arrhythmias.

Abstract: Novel gene, rin2, and encoded protein are disclosed which can inhibit the functional response induced by Ras-dependent signaling pathways are disclosed. Methods of inhibiting or enhancing Ras-dependent signaling and methods of treatment utilizing Rin2 are also disclosed.

Abstract: A VLSI layout editor and method for using same that increases display and re-display speed and accuracy uses properties inherent to VLSI layouts that allows them to be displayed efficiently and accurately independent of the canonical expression of the VLSI design. The VLSI layout editor and methods for using same use precomputed images that each represent a portion of the VLSI layout, a hierarchy cache that includes multiple LOD versions of selected sub-designs in the pre-computed images, and selected direct determination of the viewable representation from the canonical expression for at least one LOD. Apparatus and methods according to the present invention can render a particular type of data whose canonical form is smaller than its corresponding displayed image thereof when the displayed image has geometric properties that allow heuristics and rasterization for dynamic and accurate expansion using selected combined techniques.

Abstract: A VLSI layout editor and method for using same that increases display and re-display speed and accuracy uses properties inherent to VLSI layouts that allows them to be displayed efficiently and accurately independent of the canonical expression of the VLSI design. The VLSI layout editor and methods for using same use precomputed images that each represent a portion of the VLSI layout, a hierarchy cache that includes multiple LOD versions of selected sub-designs in the pre-computed images, and selected direct determination of the viewable representation from the canonical expression for at least one LOD. Apparatus and methods according to the present invention can render a particular type of data whose canonical form is smaller than its corresponding displayed image thereof when the displayed image has geometric properties that allow heuristics and rasterization for dynamic and accurate expansion using selected combined techniques.

Abstract: Methods are disclosed for diagnosing urinary incontinence or a predisposition to urinary incontinence in a subject by determining the ratio of expression levels of MMPs/TIMPs in pelvic supporting tissue of the subject and comparing the ratio to a predetermined indicator. A diagnostic kit is also disclosed. Methods are disclosed for treating urinary incontinence by reducing proteolysis of collagen in pelvic supporting tissue of the subject and for identifying therapeutic agents in in vitro screens.

Abstract: The present invention features methods for induction of angiogenesis by administration of nicotine or other nicotine receptor agonist. Induction of angiogenesis by the methods of the invention can be used in therapeutic angiogenesis in, for example, treatment of ischemic syndromes such as coronary or peripheral arterial disease.

Abstract: The present invention relates to the isolation and sequencing of a novel class of methyltransferase genes, including the methyltransferase gene from Rhizobium meliloti, Agrobacterium tumefaciens, Brucella abortus, and Helicobacter pylori. The invention further comprises efficient methods of assaying methyltransferase activity.

Abstract: A copolymer of ethylene and at least one comonomer containing at least 4 carbon atoms is characterized by a polydispersity greater than 2, a broad melting point transition as measured by differential scanning calorimetry, and a narrow composition distribution. Ethylene/C4+ copolymers also may show at least one peak melting point above the peak melting point of a random copolymer of the same monomer unit composition. These copolymers are made by contacting ethylene and a comonomer under polymerization conditions in the presence of a suitable fluxional catalyst system.

Abstract: Bifunctional molecules and methods for their use in the production of binary complexes in a host are provided. The bifunctional molecule is a conjugate of a drug moiety and a presenter protein ligand. The molecular weight of the bifunctional molecule is preferably less than about 5000 daltons, and the drug moiety may have a molecular weight of from about 50 to 2000 daltons. The drug moiety and presenter protein ligand may be covalently linked directly or through a linking group. The drug moiety binds to a drug target such as a protein and the presenter protein ligand binds to a presenter protein that is not the drug target such as extracellular or intracellular protein. Presenter proteins include peptidyl prolyl isomerase (FKBP), Heat Shock Protein 90 (Hsp90), steroid hormone receptors, cytoskeletal proteins, albumin and vitamin receptors.

Abstract: Methods and compositions for transporting drugs and macromolecules across biological membranes are disclosed. In one embodiment, the invention includes a method for enhancing transport of a selected compound across a biological membrane, wherein a biological membrane is contacted with a conjugate containing a biologically active agent that is covalently attached to a transport polymer. In one embodiment, the polymer consists of from 6 to 25 subunits, at least 50% of which contain a guanidino or amidino sidechain moiety. The polymer is effective to impart to the attached agent a rate of trans-membrane transport across a biological membrane that is greater than the rate of trans-membrane transport of the agent in nonconjugated form.

Abstract: Novel P element derived vectors and methods for their use to insert an exogenous nucleic acid into the genome of a target cell are provided. The subject vectors have a pair of P element transposase recognized insertion sites, e.g. 31 base pair inverted repeats, flanking at least two transcriptionally active genes. In practicing the subject methods, a vector of the subject invention is introduced into the target cell under conditions sufficient for transposition to occur. The subject methods find use in a variety of applications in which the insertion of an exogenous nucleic acid into the genome of a target cell is desired, e.g. include research, synthesis and therapeutic applications.